Pulmonary Embolism Treatment and Management

Anticoagulants, or blood thinners, are the cornerstone of treatment for the vast majority of PE cases. They do not dissolve the clot but prevent it from growing and allow the body’s natural fibrinolytic system to break it down over time.

• Initial Parenteral Anticoagulation: For patients admitted to the hospital, treatment often begins with injectable medications. Unfractionated Heparin (UFH) is administered intravenously and requires frequent monitoring of blood clotting times (aPTT). Low Molecular Weight Heparin (LMWH), such as enoxaparin, is given subcutaneously and has a more predictable response, often not requiring monitoring. Fondaparinux is another injectable option.
• Direct Oral Anticoagulants (DOACs): These have revolutionized the treatment of PE. Drugs like apixaban, rivaroxaban, dabigatran, and edoxaban are pills that work rapidly and do not require routine blood monitoring or dietary restrictions. They are now the preferred long-term treatment for most patients.

Vitamin K Antagonists: Warfarin is the traditional oral blood thinner. It requires careful monitoring of the INR (International Normalized Ratio) and is affected by diet (vitamin K intake) and many other medications. It is reserved for patients with severe renal failure, antiphospholipid syndrome, or mechanical heart valves.